Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Brenda J. Foster"'
Autor:
Zhihui Lang, Mark R. Albertini, Marielena Mata, Heidi Schalch, Steven J. O'Day, Omid Hamid, Manjula Reddy, Brenda J. Foster, Anna C. Pavlick, Jie Ling
Publikováno v:
Investigational New Drugs. 30:1074-1081
Purpose In this Phase 1, multicenter, open-label study, intetumumab (CNTO 95), a fully human anti-αv integrin monoclonal antibody was evaluated for safety, pharmacokinetics, and pharmacodynamic activity in patients with melanoma or angiosarcoma. Pat
Publikováno v:
Cancer Chemotherapy and Pharmacology. 54:89-94
Acetyldinaline (CI-994) has shown preclinical efficacy in vitro and in vivo against solid tumor and leukemia cell lines. Since myelosuppression was the dose-limiting toxicity for acetyldinaline in preclinical and clinical studies, experiments were co
Autor:
Lance K. Heilbrun, Mark Bradley Meyer, Mark M. Zalupski, Patricia LoRusso, Manuel Valdivieso, Louis L. Radulovic, Lawrence E. Flaherty, Antoinette J. Wozniak, Brenda J. Foster, Sucharu Prakash
Publikováno v:
Investigational New Drugs. 19:1-11
Objectives: CI-994 (N-acetyl dinaline, PD123654) is a novel oral agent active in a broad variety ofmurine and human tumor xenografts. While cytotoxic in theBrown Norway (BN) rat leukemia model, growth inhibition inother murine and human tumor xenogra
Publikováno v:
Investigational New Drugs. 16:199-204
Cryptophycin 1 is a natural product that was initially isolated from blue-green algae which has shown potent broad spectrum antitumor activity in preclinical in vitro and in vivo models. The drug strongly binds to tubulin and disrupts microtubule ass
Publikováno v:
Investigational New Drugs. 15:187-194
CI-994, a substituted benzamide derivative, is a compound that showed solid tumor selectivity for a variety of solid tumor models compared to L1210 leukemia. Due to its lack of aqueous solubility, it requires oral administration. Female B6D2F1 mice w
Autor:
Richard Wiegand, Laurence H. Baker, Thomas H. Corbett, Jerome P. Horwitz, Brenda J. Foster, Eduardo Palomino, Maya B. Kempff
Publikováno v:
Cancer Chemotherapy and Pharmacology. 38:453-458
Purpose. Pyrazoloacridine (PZA) is a newly developed anticancer agent currently undergoing clinical trials. Its mode of action has not been elucidated but the presence in its chemical structure of a 5-nitro functional group and its activity against o
Autor:
Judith Sebolt, Janet Dzubow, Laura Biernat, Wilbur R. Leopold, Gregory M. L. Patterson, Loretta Lisow, Robert B. Perni, Lynne Jones, Sarpotdar Pramod P, J. C. Knight, Susan A. Coughlin, Mark P. Wentland, Lisa Demchik, Nancy Lowichik, Gary Liversidge, Fred Valeriote, Manuel Valdivieso, Susan Pugh, Antoinette J. Wozniak, Julie Jones, Patricia LoRusso, Marie Christine Bissery, Lisa Polin, Brenda J. Foster, Chiab Panchapor, Bruno Joseph A, Thomas H. Corbett, Lawrence H. Baker, J Michael Shaw, Ken C. Mattes, Elaine Liversidge, Richard E. Moore, James B. Rake, Kathryn White
Publikováno v:
International Journal of Pharmacognosy. 33:102-122
Each independently arising tumor is a separate and unique biologic entity with its own unique histologic appearance, biologic behavior, and drug response profile. Thus, in drug discovery, no single tumor has been a perfect predictor for any other tum
Autor:
Kenneth C. Mattes, Chiab Panchapor, Patricia LoRusso, Susan A. Coughlin, Lance K. Heilbrun, James B. Rake, Kathryn White, Mark P. Wentland, Thomas H. Corbett, Jui Wanna Knight, Brenda J. Foster, Laurence H. Baker, Lisa Demchik, Lisa Polin, Fred Valeriote, Nancy Lowichik, Julie Jones, Lynne Jones, Susan Pugh, Ronald G. Powles, Robert Bruno Perni, Allan G. Hlavac, Laura Biernat
Publikováno v:
Expert Opinion on Investigational Drugs. 3:1281-1292
WIN33377 (Sterling/Kodak) entered Phase I clinical trials in 1994. The dose limiting toxicity has not been reached with completion of the 225 mg/m2 level, Q28 day schedule. To date, the agent has been very well tolerated with no evidence of liver tox
Autor:
C L Fortner, Clagett-Carr K, D. E. Hoth, Brian Leyland-Jones, D. Macfarlane, Larry Rubinstein, Brenda J. Foster, G. Sarosy, Peter J. O'Dwyer, B. R. Davies, D. Dale Shoemaker, H. G. Chun
Publikováno v:
Annals of Oncology. 3:59-62
Summary The special exception mechanism was established by the Division of Cancer Treatment (DCT), National Cancer Institute (NCI), for the provision of anticancer drugs not yet approved by the Food and Drug Administration (FDA) to patients on a comp
Autor:
Brenda J. Foster, Robert H. Earhart, Elizabeth Poplin, Dorothy A. Kasunic, Manuel Valdivieso, Laurence H. Baker, Patricia LoRusso, Lawrence E. Flaherty, Mark M. Zalupski, Antoinette J. Wozniak
Publikováno v:
Investigational new drugs. 13(4)
CC-1065 is a unique alkylating agent that preferentially binds in the minor groove of double-stranded DNA at adenine-thymine-rich sites. Although it has broad antitumor activity in preclinical models its development was discontinued because of deaths